- Home
- PHAR vs ORIC Comparison
PHAR vs ORIC Comparison
Compare PHAR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ORIC
- Stock Information
- Founded
- PHAR 1988
- ORIC 2014
- Country
- PHAR Netherlands
- ORIC United States
- Employees
- PHAR N/A
- ORIC N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- ORIC Health Care
- Exchange
- PHAR Nasdaq
- ORIC Nasdaq
- Market Cap
- PHAR 618.3M
- ORIC 735.3M
- IPO Year
- PHAR N/A
- ORIC 2020
- Fundamental
- Price
- PHAR $8.42
- ORIC $11.08
- Analyst Decision
- PHAR Strong Buy
- ORIC Strong Buy
- Analyst Count
- PHAR 3
- ORIC 9
- Target Price
- PHAR $27.00
- ORIC $18.75
- AVG Volume (30 Days)
- PHAR 5.6K
- ORIC 825.1K
- Earning Date
- PHAR 03-13-2025
- ORIC 03-10-2025
- Dividend Yield
- PHAR N/A
- ORIC N/A
- EPS Growth
- PHAR N/A
- ORIC N/A
- EPS
- PHAR N/A
- ORIC N/A
- Revenue
- PHAR $285,745,000.00
- ORIC N/A
- Revenue This Year
- PHAR $20.08
- ORIC N/A
- Revenue Next Year
- PHAR $9.22
- ORIC N/A
- P/E Ratio
- PHAR N/A
- ORIC N/A
- Revenue Growth
- PHAR 30.64
- ORIC N/A
- 52 Week Low
- PHAR $6.65
- ORIC $6.33
- 52 Week High
- PHAR $13.20
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- PHAR 40.05
- ORIC 59.70
- Support Level
- PHAR $7.95
- ORIC $9.95
- Resistance Level
- PHAR $9.35
- ORIC $12.01
- Average True Range (ATR)
- PHAR 0.52
- ORIC 0.86
- MACD
- PHAR -0.16
- ORIC 0.04
- Stochastic Oscillator
- PHAR 22.76
- ORIC 64.50
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.